Bristol Myers strikes $4.1 bln RayzeBio deal for targeted cancer therapies

With the RayzeBio deal, Bristol gains a late-stage targeted cancer therapy that uses radioactive particles to kill tumor cells. The drug, called RYZ101 by RayzeBio, is being tested in late-stage studies for a rare type of pancreatic cancer.